Occam Places CEO for RadioPharm Start-Up
ARTBIO was founded by Roy Larsen, PhD inventor of the technology behind the breakthrough radiotherapeutic cancer drug, Xofigo. Occam placed Emanuele Ostuni, PhD the former head of Novartis Oncology's cell and gene therapy unit in Europe, as CEO.
The global start-up with offices in Oslo, London, Basel, and Boston just emerged from stealth with a robust pipeline and $23M from an international syndicate of investors, including F-Prime Capital and Omega Funds.
ARTBIO's board includes Ted Love, CEO of Global Blood Therapeutics until its $5.4B acquisition by Pfizer, and Susanne Schaffert, former President of Novartis Oncology. ARTBIO's lead asset in prostate cancer entered the clinic and will be developed quickly alongside other internal pipeline programs.
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.